While eight in every hundred Australians has a rare disease, GPs lack confidence in identifying these patients, which may delay diagnosis and treatment.

Most respondents to an AusDoc survey prescribe weight-loss medications at least once a month, with legacy products enjoying strong brand recall alongside the newer entrants to the market.

More than 85% of doctors report an increased number of patients asking about weight-loss medication over the past 12 months, but many lack confidence to discuss newer treatments, according to an exclusive AusDoc survey.

Even though Pfizer’s customers prefer face-to-face, most of their engagement is digital, writes Clifford Fram, director of partnerships and innovation at adg. Claire Edgerton’s morning fix is to check the data. She likes to know what content and channels Pfizer’s customers are engaging with – what they’re reading, what they’re watching and what they’re searching

The digital revolution has had a significant positive impact on how doctors’ access pharmaceutical information, especially in the post-COVID-19 era. This has ultimately enhanced the quality use of medicines and patient care. More recently, with the ubiquitous use of the word ’omnichannel’, the short-term challenge for pharma is finding the right mix between traditional face-to-face

A recent AusDoc survey of 418 GPs and GP registrars focusing on pathology tests has uncovered a raft of unmet needs for GP education, and opened up a range of opportunities for pathology organisations and pharma companies to offer meaningful med ed. Respondents were crying out for further education, with several key areas of particular

Pathology testing and the interpretation of results are regular challenges for many GPs, and there are several key areas that are particularly problematic, an AusDoc survey of 418 GPs and GP registrars has revealed. 1. Ordering tests: vague symptoms pose problems When it comes to deciding which pathology tests to order, the clinical presentations that